AC Immune S.A. (ACIU) 10-Year Financial Performance & Capital Metrics

ACIU • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Show more

Revenue $27M +84.5%
EBITDA -$50M +2.3%
Net Income -$51M +6.1%
EPS (Diluted) -0.51 +20.3%
Gross Margin -129.12% +52.0%
EBITDA Margin -183.88% +47.1%
Operating Margin -191.8% +47.1%
Net Margin -186.44% +49.1%
ROE -37.31% -13.4%
ROIC -47.03% -32.0%
Debt/Equity 0.05 +122.1%
Interest Coverage -393.82 -29.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 239.0% free cash flow margin
✓Momentum leader: RS Rating 88 (top 12%)

✗Weaknesses

✗Sales declining 24.4% over 5 years
✗Shares diluted 17.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-1.02%

5Y-24.38%

3Y-

TTM-89.33%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-80.3%

EPS CAGR

10Y-

5Y-

3Y-

TTM-70.51%

ROCE

10Y Avg-16.06%

5Y Avg-31.67%

3Y Avg-33.42%

Latest-35%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	39.09M	23.21M	20.25M	7.19M	110.46M	15.43M	0	3.94M	14.8M	27.31M
Revenue Growth %	0.29%	-0.41%	-0.13%	-0.64%	14.35%	-0.86%	-1%	-	2.76%	0.85%
Cost of Goods Sold+	17.05M	25.77M	32.66M	44.28M	50.43M	59.49M	0	0	54.61M	62.57M
COGS % of Revenue	0.44%	1.11%	1.61%	6.15%	0.46%	3.86%	-	-	3.69%	2.29%
Gross Profit+	22.04M	-2.56M	-12.41M	-37.08M	60.02M	-44.06M	0	3.94M	-39.8M	-35.26M
Gross Margin %	0.56%	-0.11%	-0.61%	-5.15%	0.54%	-2.86%	-	1%	-2.69%	-1.29%
Gross Profit Growth %	0.56%	-1.12%	-3.85%	-1.99%	2.62%	-1.73%	1%	-	-11.12%	0.11%
Operating Expenses+	20.47M	33.67M	42.79M	56.74M	15.49M	17.2M	79.01M	74.78M	13.82M	17.12M
OpEx % of Revenue	0.52%	1.45%	2.11%	7.89%	0.14%	1.11%	-	19%	0.93%	0.63%
Selling, General & Admin	2.04M	4.73M	6.27M	7.56M	16.06M	18.56M	10.88M	9.58M	10.58M	11.43M
SG&A % of Revenue	0.05%	0.2%	0.31%	1.05%	0.15%	1.2%	-	2.44%	0.71%	0.42%
Research & Development	17.05M	25.77M	32.66M	44.28M	50.43M	59.49M	62.28M	60.34M	54.61M	62.57M
R&D % of Revenue	0.44%	1.11%	1.61%	6.15%	0.46%	3.86%	-	15.33%	3.69%	2.29%
Other Operating Expenses	1.38M	3.17M	3.86M	4.9M	-51M	-60.84M	5.85M	4.86M	-51.36M	-56.89M
Operating Income+	18.62M	-10.46M	-22.54M	-49.55M	44.54M	-61.26M	-79.01M	-70.85M	-53.62M	-52.38M
Operating Margin %	0.48%	-0.45%	-1.11%	-6.89%	0.4%	-3.97%	-	-18%	-3.62%	-1.92%
Operating Income Growth %	0.74%	-1.56%	-1.16%	-1.2%	1.9%	-2.38%	-0.29%	0.1%	0.24%	0.02%
EBITDA+	18.91M	-10.18M	-21.96M	-48.59M	45.81M	-59.73M	-76.6M	-68.49M	-51.41M	-50.22M
EBITDA Margin %	0.48%	-0.44%	-1.08%	-6.75%	0.41%	-3.87%	-	-17.4%	-3.47%	-1.84%
EBITDA Growth %	0.72%	-1.54%	-1.16%	-1.21%	1.94%	-2.3%	-0.28%	0.11%	0.25%	0.02%
D&A (Non-Cash Add-back)	287K	278K	580K	961K	1.27M	1.53M	2.41M	2.36M	2.21M	2.16M
EBIT	20.27M	-7.09M	-26.26M	-50.62M	44.54M	-61.26M	-72.41M	-70.39M	-54.05M	-50.78M
Net Interest Income+	48K	-83K	176K	-207K	-1.62M	-106K	5.9M	-286K	868K	3.06M
Interest Income	55K	43K	330K	127K	303K	78K	6.49M	69K	1.04M	3.2M
Interest Expense	26K	256K	147K	334K	1.93M	184K	581K	355K	176K	133K
Other Income/Expense	1.65M	3.36M	-3.87M	-1.4M	906K	-661K	6.02M	107K	-599K	1.47M
Pretax Income+	20.27M	-7.1M	-26.41M	-50.95M	45.44M	-61.92M	-72.99M	-70.74M	-54.22M	-50.91M
Pretax Margin %	0.52%	-0.31%	-1.3%	-7.08%	0.41%	-4.01%	-	-17.98%	-3.66%	-1.86%
Income Tax+	0	0	147K	0	0	0	3K	13K	10K	3K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	20.27M	-7.1M	-26.41M	-50.95M	45.44M	-61.92M	-73M	-70.75M	-54.23M	-50.92M
Net Margin %	0.52%	-0.31%	-1.3%	-7.08%	0.41%	-4.01%	-	-17.98%	-3.66%	-1.86%
Net Income Growth %	0.89%	-1.35%	-2.72%	-0.93%	1.89%	-2.36%	-0.18%	0.03%	0.23%	0.06%
Net Income (Continuing)	20.27M	-7.1M	-26.41M	-50.95M	45.44M	-61.92M	-73M	-70.75M	-54.23M	-50.92M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.37	-0.14	-0.46	-0.82	0.64	-0.86	-0.97	-0.85	-0.64	-0.51
EPS Growth %	0.95%	-1.38%	-2.29%	-0.78%	1.78%	-2.34%	-0.13%	0.12%	0.25%	0.2%
EPS (Basic)	0.37	-0.14	-0.46	-0.82	0.64	-0.86	-0.97	-0.85	-0.64	-0.51
Diluted Shares Outstanding	55.4M	50.1M	57.36M	61.84M	71.1M	71.9M	74.95M	83.55M	84.69M	99.69M
Basic Shares Outstanding	55.4M	50.1M	57.08M	61.84M	70.6M	71.9M	74.95M	83.55M	84.69M	99.69M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	79.35M	154.89M	129.53M	192.93M	292.77M	231.77M	202.63M	128.09M	125.15M	171.99M
Cash & Short-Term Investments	76.52M	152.21M	124.38M	186.46M	288.59M	225.89M	198.22M	122.59M	103.05M	165.49M
Cash Only	76.52M	152.21M	124.38M	156.46M	193.59M	160.89M	82.22M	31.59M	78.49M	36.27M
Short-Term Investments	0	0	0	30M	95M	65M	116M	91M	24.55M	129.21M
Accounts Receivable	316K	1.41M	3.72M	4.1M	1.4M	1.59M	975K	408K	15.05M	1.1M
Days Sales Outstanding	2.95	22.11	66.98	208.12	4.62	37.63	-	37.84	371.04	14.69
Inventory	2.46M	389K	-1.36M	0	0	0	0	0	0	0
Days Inventory Outstanding	52.69	5.51	-	-	-	-	-	-	-	-
Other Current Assets	2.44M	0	0	0	0	329K	428K	392K	622K	1.1M
Total Non-Current Assets+	585K	1.21M	2.48M	3.63M	6.48M	6.97M	58.81M	57.84M	57.66M	58.92M
Property, Plant & Equipment	500K	1.12M	2.35M	3.32M	6.17M	6.64M	8.03M	7.07M	6.88M	8.09M
Fixed Asset Turnover	78.18x	20.73x	8.61x	2.16x	17.90x	2.32x	-	0.56x	2.15x	3.38x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	50.42M	50.42M	50.42M	50.42M
Long-Term Investments	85K	86K	126K	304K	304K	0	0	0	361K	0
Other Non-Current Assets	0	0	0	0	0	334K	363K	361K	0	415K
Total Assets+	79.93M	156.1M	132.01M	196.56M	299.25M	238.74M	261.44M	185.94M	182.81M	230.91M
Asset Turnover	0.49x	0.15x	0.15x	0.04x	0.37x	0.06x	-	0.02x	0.08x	0.12x
Asset Growth %	1.64%	0.95%	-0.15%	0.49%	0.52%	-0.2%	0.1%	-0.29%	-0.02%	0.26%
Total Current Liabilities+	6.1M	9.92M	9.75M	13.08M	17.51M	14.02M	20.03M	11.48M	13.58M	100.84M
Accounts Payable	1.72M	4.04M	1.09M	1.98M	142K	2.18M	2M	929K	1.68M	2.66M
Days Payables Outstanding	36.8	57.14	12.2	16.31	1.03	13.4	-	-	11.22	15.51
Short-Term Debt	0	0	0	332K	652K	0	0	0	0	0
Deferred Revenue (Current)	45K	521K	355K	351K	1000K	0	0	0	138K	0
Other Current Liabilities	0	0	0	0	0	306K	717K	587K	0	85.06M
Current Ratio	13.01x	15.61x	13.28x	14.75x	16.72x	16.53x	10.12x	11.16x	9.22x	1.71x
Quick Ratio	12.60x	15.57x	13.42x	14.75x	16.72x	16.53x	10.12x	11.16x	9.22x	1.71x
Cash Conversion Cycle	18.84	-29.53	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.79M	3.8M	5.42M	5.85M	9.3M	9.24M	9.44M	5.47M	8.6M	17.8M
Long-Term Debt	0	0	494K	186K	0	0	0	0	0	0
Capital Lease Obligations	0	0	395K	0	1.81M	1.78M	2.34M	2.25M	2.83M	4.4M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.79M	3.8M	4.53M	5.67M	7.49M	7.46M	7.1M	3.21M	5.77M	13.4M
Total Liabilities	8.89M	13.72M	15.17M	18.93M	26.81M	23.26M	29.46M	16.95M	22.17M	118.64M
Total Debt+	0	0	395K	518K	2.91M	2.22M	2.91M	2.8M	3.5M	5.43M
Net Debt	-76.52M	-152.21M	-123.98M	-155.94M	-190.68M	-158.67M	-79.31M	-28.79M	-75M	-30.85M
Debt / Equity	-	-	0.00x	0.00x	0.01x	0.01x	0.01x	0.02x	0.02x	0.05x
Debt / EBITDA	-	-	-	-	0.06x	-	-	-	-	-
Net Debt / EBITDA	-4.05x	-	-	-	-4.16x	-	-	-	-	-
Interest Coverage	716.31x	-40.84x	-153.33x	-148.35x	23.12x	-332.93x	-135.99x	-199.57x	-304.68x	-393.82x
Total Equity+	71.04M	142.38M	116.84M	177.62M	272.44M	215.48M	231.98M	168.99M	160.64M	112.27M
Equity Growth %	2.03%	1%	-0.18%	0.52%	0.53%	-0.21%	0.08%	-0.27%	-0.05%	-0.3%
Book Value per Share	1.28	2.84	2.04	2.87	3.83	3.00	3.10	2.02	1.90	1.13
Total Shareholders' Equity	71.04M	142.38M	116.84M	177.62M	272.44M	215.48M	231.98M	168.99M	160.64M	112.27M
Common Stock	928K	1.14M	1.15M	1.35M	1.44M	1.54M	1.79M	1.8M	2.09M	2.23M
Retained Earnings	-40.38M	-46.92M	-72.61M	-121.88M	-75.52M	-132.85M	-200.94M	-264.01M	-316.2M	-368.24M
Treasury Stock	0	0	0	0	0	-100K	-124K	-124K	-105K	-218K
Accumulated OCI	-1.88M	-2.15M	179.35M	-3.54M	0	0	0	10K	-51K	-5K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	44.08M	-5.65M	-22.09M	-44.08M	55.22M	-59.52M	-65.69M	-73.57M	-60.41M	65.84M
Operating CF Margin %	1.13%	-0.24%	-1.09%	-6.13%	0.5%	-3.86%	-	-18.7%	-4.08%	2.41%
Operating CF Growth %	3.5%	-1.13%	-2.91%	-1%	2.25%	-2.08%	-0.1%	-0.12%	0.18%	2.09%
Net Income	20.27M	-7.1M	-26.41M	-50.95M	45.44M	-61.92M	-73M	-70.75M	-54.23M	-50.92M
Depreciation & Amortization	287K	278K	580K	961K	1.69M	1.97M	2.41M	2.36M	2.21M	2.16M
Stock-Based Compensation	540K	1.32M	1.58M	2.52M	2.83M	4.09M	4.13M	3.33M	4.37M	5.47M
Deferred Taxes	49K	-83K	177K	131K	0	0	130K	0	0	0
Other Non-Cash Items	-1.65M	-3.36M	3.97M	1.45M	-400K	922K	-6.2M	-72K	2.4M	1.61M
Working Capital Changes	24.58M	3.3M	-1.99M	1.81M	5.65M	-4.57M	6.84M	-8.43M	-15.16M	107.51M
Change in Receivables	25.67M	-248K	-401K	698K	2.5M	-532K	-99K	603K	-14.8M	13.55M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-141K	2.59M	-2.85M	0	0	0	0	0	0	0
Cash from Investing+	-244K	-899K	-1.84M	-32.04M	-66.89M	28.33M	-53.66M	23.76M	65.64M	-105.29M
Capital Expenditures	-244K	-899K	-1.8M	-1.86M	-1.89M	-1.71M	-2.63M	-1.24M	-801K	-576K
CapEx % of Revenue	0.01%	0.04%	0.09%	0.26%	0.02%	0.11%	-	0.31%	0.05%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-40K	-178K	0	30.04M	-51.03M	25M	66.45M	-104.71M
Cash from Financing+	27.78M	78.79M	271K	109.38M	49.62M	-803K	40.75M	-1.35M	43.25M	-1.12M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.78M	-4.11M	71K	-2.35M	-441K	143K	-6K	-776K	0	-548K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	43.84M	-6.54M	-23.9M	-45.94M	53.34M	-61.22M	-68.32M	-74.81M	-61.21M	65.27M
FCF Margin %	1.12%	-0.28%	-1.18%	-6.39%	0.48%	-3.97%	-	-19.01%	-4.14%	2.39%
FCF Growth %	3.47%	-1.15%	-2.65%	-0.92%	2.16%	-2.15%	-0.12%	-0.09%	0.18%	2.07%
FCF per Share	0.79	-0.13	-0.42	-0.74	0.75	-0.85	-0.91	-0.90	-0.72	0.65
FCF Conversion (FCF/Net Income)	2.17x	0.80x	0.84x	0.87x	1.22x	0.96x	0.90x	1.04x	1.11x	-1.29x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	42.89%	-6.65%	-20.38%	-34.61%	20.19%	-25.38%	-32.63%	-35.29%	-32.91%	-37.31%
Return on Invested Capital (ROIC)	190.27%	-	-	-511.32%	64.58%	-66.31%	-56.58%	-36.28%	-35.61%	-47.03%
Gross Margin	56.39%	-11.03%	-61.26%	-515.47%	54.34%	-285.5%	-	100%	-268.93%	-129.12%
Net Margin	51.85%	-30.57%	-130.39%	-708.24%	41.14%	-401.28%	-	-1798.04%	-366.41%	-186.44%
Debt / Equity	-	-	0.00x	0.00x	0.01x	0.01x	0.01x	0.02x	0.02x	0.05x
Interest Coverage	716.31x	-40.84x	-153.33x	-148.35x	23.12x	-332.93x	-135.99x	-199.57x	-304.68x	-393.82x
FCF Conversion	2.17x	0.80x	0.84x	0.87x	1.22x	0.96x	0.90x	1.04x	1.11x	-1.29x
Revenue Growth	29.14%	-40.61%	-12.75%	-64.48%	1435.39%	-86.03%	-100%	-	276.14%	84.51%

Frequently Asked Questions

Growth & Financials

AC Immune S.A. (ACIU) reported $4.4M in revenue for fiscal year 2024. This represents a 49% decrease from $8.6M in 2013.

AC Immune S.A. (ACIU) grew revenue by 84.5% over the past year. This is strong growth.

AC Immune S.A. (ACIU) reported a net loss of $71.9M for fiscal year 2024.

Dividend & Returns

AC Immune S.A. (ACIU) has a return on equity (ROE) of -37.3%. Negative ROE indicates the company is unprofitable.

AC Immune S.A. (ACIU) had negative free cash flow of $47.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

AC Immune S.A. (ACIU) 10-Year Financial Performance & Capital Metrics

ACIU • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $27M +84.5%
EBITDA -$50M +2.3%
Net Income -$51M +6.1%
EPS (Diluted) -0.51 +20.3%
Gross Margin -129.12% +52.0%
EBITDA Margin -183.88% +47.1%
Operating Margin -191.8% +47.1%
Net Margin -186.44% +49.1%
ROE -37.31% -13.4%
ROIC -47.03% -32.0%
Debt/Equity 0.05 +122.1%
Interest Coverage -393.82 -29.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 239.0% free cash flow margin
✓Momentum leader: RS Rating 88 (top 12%)

✗Weaknesses

✗Sales declining 24.4% over 5 years
✗Shares diluted 17.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-1.02%

5Y-24.38%

3Y-

TTM-89.33%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-80.3%

EPS CAGR

10Y-

5Y-

3Y-

TTM-70.51%

ROCE

10Y Avg-16.06%

5Y Avg-31.67%

3Y Avg-33.42%

Latest-35%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	39.09M	23.21M	20.25M	7.19M	110.46M	15.43M	0	3.94M	14.8M	27.31M
Revenue Growth %	0.29%	-0.41%	-0.13%	-0.64%	14.35%	-0.86%	-1%	-	2.76%	0.85%
Cost of Goods Sold+	17.05M	25.77M	32.66M	44.28M	50.43M	59.49M	0	0	54.61M	62.57M
COGS % of Revenue	0.44%	1.11%	1.61%	6.15%	0.46%	3.86%	-	-	3.69%	2.29%
Gross Profit+	22.04M	-2.56M	-12.41M	-37.08M	60.02M	-44.06M	0	3.94M	-39.8M	-35.26M
Gross Margin %	0.56%	-0.11%	-0.61%	-5.15%	0.54%	-2.86%	-	1%	-2.69%	-1.29%
Gross Profit Growth %	0.56%	-1.12%	-3.85%	-1.99%	2.62%	-1.73%	1%	-	-11.12%	0.11%
Operating Expenses+	20.47M	33.67M	42.79M	56.74M	15.49M	17.2M	79.01M	74.78M	13.82M	17.12M
OpEx % of Revenue	0.52%	1.45%	2.11%	7.89%	0.14%	1.11%	-	19%	0.93%	0.63%
Selling, General & Admin	2.04M	4.73M	6.27M	7.56M	16.06M	18.56M	10.88M	9.58M	10.58M	11.43M
SG&A % of Revenue	0.05%	0.2%	0.31%	1.05%	0.15%	1.2%	-	2.44%	0.71%	0.42%
Research & Development	17.05M	25.77M	32.66M	44.28M	50.43M	59.49M	62.28M	60.34M	54.61M	62.57M
R&D % of Revenue	0.44%	1.11%	1.61%	6.15%	0.46%	3.86%	-	15.33%	3.69%	2.29%
Other Operating Expenses	1.38M	3.17M	3.86M	4.9M	-51M	-60.84M	5.85M	4.86M	-51.36M	-56.89M
Operating Income+	18.62M	-10.46M	-22.54M	-49.55M	44.54M	-61.26M	-79.01M	-70.85M	-53.62M	-52.38M
Operating Margin %	0.48%	-0.45%	-1.11%	-6.89%	0.4%	-3.97%	-	-18%	-3.62%	-1.92%
Operating Income Growth %	0.74%	-1.56%	-1.16%	-1.2%	1.9%	-2.38%	-0.29%	0.1%	0.24%	0.02%
EBITDA+	18.91M	-10.18M	-21.96M	-48.59M	45.81M	-59.73M	-76.6M	-68.49M	-51.41M	-50.22M
EBITDA Margin %	0.48%	-0.44%	-1.08%	-6.75%	0.41%	-3.87%	-	-17.4%	-3.47%	-1.84%
EBITDA Growth %	0.72%	-1.54%	-1.16%	-1.21%	1.94%	-2.3%	-0.28%	0.11%	0.25%	0.02%
D&A (Non-Cash Add-back)	287K	278K	580K	961K	1.27M	1.53M	2.41M	2.36M	2.21M	2.16M
EBIT	20.27M	-7.09M	-26.26M	-50.62M	44.54M	-61.26M	-72.41M	-70.39M	-54.05M	-50.78M
Net Interest Income+	48K	-83K	176K	-207K	-1.62M	-106K	5.9M	-286K	868K	3.06M
Interest Income	55K	43K	330K	127K	303K	78K	6.49M	69K	1.04M	3.2M
Interest Expense	26K	256K	147K	334K	1.93M	184K	581K	355K	176K	133K
Other Income/Expense	1.65M	3.36M	-3.87M	-1.4M	906K	-661K	6.02M	107K	-599K	1.47M
Pretax Income+	20.27M	-7.1M	-26.41M	-50.95M	45.44M	-61.92M	-72.99M	-70.74M	-54.22M	-50.91M
Pretax Margin %	0.52%	-0.31%	-1.3%	-7.08%	0.41%	-4.01%	-	-17.98%	-3.66%	-1.86%
Income Tax+	0	0	147K	0	0	0	3K	13K	10K	3K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	20.27M	-7.1M	-26.41M	-50.95M	45.44M	-61.92M	-73M	-70.75M	-54.23M	-50.92M
Net Margin %	0.52%	-0.31%	-1.3%	-7.08%	0.41%	-4.01%	-	-17.98%	-3.66%	-1.86%
Net Income Growth %	0.89%	-1.35%	-2.72%	-0.93%	1.89%	-2.36%	-0.18%	0.03%	0.23%	0.06%
Net Income (Continuing)	20.27M	-7.1M	-26.41M	-50.95M	45.44M	-61.92M	-73M	-70.75M	-54.23M	-50.92M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.37	-0.14	-0.46	-0.82	0.64	-0.86	-0.97	-0.85	-0.64	-0.51
EPS Growth %	0.95%	-1.38%	-2.29%	-0.78%	1.78%	-2.34%	-0.13%	0.12%	0.25%	0.2%
EPS (Basic)	0.37	-0.14	-0.46	-0.82	0.64	-0.86	-0.97	-0.85	-0.64	-0.51
Diluted Shares Outstanding	55.4M	50.1M	57.36M	61.84M	71.1M	71.9M	74.95M	83.55M	84.69M	99.69M
Basic Shares Outstanding	55.4M	50.1M	57.08M	61.84M	70.6M	71.9M	74.95M	83.55M	84.69M	99.69M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	79.35M	154.89M	129.53M	192.93M	292.77M	231.77M	202.63M	128.09M	125.15M	171.99M
Cash & Short-Term Investments	76.52M	152.21M	124.38M	186.46M	288.59M	225.89M	198.22M	122.59M	103.05M	165.49M
Cash Only	76.52M	152.21M	124.38M	156.46M	193.59M	160.89M	82.22M	31.59M	78.49M	36.27M
Short-Term Investments	0	0	0	30M	95M	65M	116M	91M	24.55M	129.21M
Accounts Receivable	316K	1.41M	3.72M	4.1M	1.4M	1.59M	975K	408K	15.05M	1.1M
Days Sales Outstanding	2.95	22.11	66.98	208.12	4.62	37.63	-	37.84	371.04	14.69
Inventory	2.46M	389K	-1.36M	0	0	0	0	0	0	0
Days Inventory Outstanding	52.69	5.51	-	-	-	-	-	-	-	-
Other Current Assets	2.44M	0	0	0	0	329K	428K	392K	622K	1.1M
Total Non-Current Assets+	585K	1.21M	2.48M	3.63M	6.48M	6.97M	58.81M	57.84M	57.66M	58.92M
Property, Plant & Equipment	500K	1.12M	2.35M	3.32M	6.17M	6.64M	8.03M	7.07M	6.88M	8.09M
Fixed Asset Turnover	78.18x	20.73x	8.61x	2.16x	17.90x	2.32x	-	0.56x	2.15x	3.38x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	50.42M	50.42M	50.42M	50.42M
Long-Term Investments	85K	86K	126K	304K	304K	0	0	0	361K	0
Other Non-Current Assets	0	0	0	0	0	334K	363K	361K	0	415K
Total Assets+	79.93M	156.1M	132.01M	196.56M	299.25M	238.74M	261.44M	185.94M	182.81M	230.91M
Asset Turnover	0.49x	0.15x	0.15x	0.04x	0.37x	0.06x	-	0.02x	0.08x	0.12x
Asset Growth %	1.64%	0.95%	-0.15%	0.49%	0.52%	-0.2%	0.1%	-0.29%	-0.02%	0.26%
Total Current Liabilities+	6.1M	9.92M	9.75M	13.08M	17.51M	14.02M	20.03M	11.48M	13.58M	100.84M
Accounts Payable	1.72M	4.04M	1.09M	1.98M	142K	2.18M	2M	929K	1.68M	2.66M
Days Payables Outstanding	36.8	57.14	12.2	16.31	1.03	13.4	-	-	11.22	15.51
Short-Term Debt	0	0	0	332K	652K	0	0	0	0	0
Deferred Revenue (Current)	45K	521K	355K	351K	1000K	0	0	0	138K	0
Other Current Liabilities	0	0	0	0	0	306K	717K	587K	0	85.06M
Current Ratio	13.01x	15.61x	13.28x	14.75x	16.72x	16.53x	10.12x	11.16x	9.22x	1.71x
Quick Ratio	12.60x	15.57x	13.42x	14.75x	16.72x	16.53x	10.12x	11.16x	9.22x	1.71x
Cash Conversion Cycle	18.84	-29.53	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.79M	3.8M	5.42M	5.85M	9.3M	9.24M	9.44M	5.47M	8.6M	17.8M
Long-Term Debt	0	0	494K	186K	0	0	0	0	0	0
Capital Lease Obligations	0	0	395K	0	1.81M	1.78M	2.34M	2.25M	2.83M	4.4M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.79M	3.8M	4.53M	5.67M	7.49M	7.46M	7.1M	3.21M	5.77M	13.4M
Total Liabilities	8.89M	13.72M	15.17M	18.93M	26.81M	23.26M	29.46M	16.95M	22.17M	118.64M
Total Debt+	0	0	395K	518K	2.91M	2.22M	2.91M	2.8M	3.5M	5.43M
Net Debt	-76.52M	-152.21M	-123.98M	-155.94M	-190.68M	-158.67M	-79.31M	-28.79M	-75M	-30.85M
Debt / Equity	-	-	0.00x	0.00x	0.01x	0.01x	0.01x	0.02x	0.02x	0.05x
Debt / EBITDA	-	-	-	-	0.06x	-	-	-	-	-
Net Debt / EBITDA	-4.05x	-	-	-	-4.16x	-	-	-	-	-
Interest Coverage	716.31x	-40.84x	-153.33x	-148.35x	23.12x	-332.93x	-135.99x	-199.57x	-304.68x	-393.82x
Total Equity+	71.04M	142.38M	116.84M	177.62M	272.44M	215.48M	231.98M	168.99M	160.64M	112.27M
Equity Growth %	2.03%	1%	-0.18%	0.52%	0.53%	-0.21%	0.08%	-0.27%	-0.05%	-0.3%
Book Value per Share	1.28	2.84	2.04	2.87	3.83	3.00	3.10	2.02	1.90	1.13
Total Shareholders' Equity	71.04M	142.38M	116.84M	177.62M	272.44M	215.48M	231.98M	168.99M	160.64M	112.27M
Common Stock	928K	1.14M	1.15M	1.35M	1.44M	1.54M	1.79M	1.8M	2.09M	2.23M
Retained Earnings	-40.38M	-46.92M	-72.61M	-121.88M	-75.52M	-132.85M	-200.94M	-264.01M	-316.2M	-368.24M
Treasury Stock	0	0	0	0	0	-100K	-124K	-124K	-105K	-218K
Accumulated OCI	-1.88M	-2.15M	179.35M	-3.54M	0	0	0	10K	-51K	-5K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	44.08M	-5.65M	-22.09M	-44.08M	55.22M	-59.52M	-65.69M	-73.57M	-60.41M	65.84M
Operating CF Margin %	1.13%	-0.24%	-1.09%	-6.13%	0.5%	-3.86%	-	-18.7%	-4.08%	2.41%
Operating CF Growth %	3.5%	-1.13%	-2.91%	-1%	2.25%	-2.08%	-0.1%	-0.12%	0.18%	2.09%
Net Income	20.27M	-7.1M	-26.41M	-50.95M	45.44M	-61.92M	-73M	-70.75M	-54.23M	-50.92M
Depreciation & Amortization	287K	278K	580K	961K	1.69M	1.97M	2.41M	2.36M	2.21M	2.16M
Stock-Based Compensation	540K	1.32M	1.58M	2.52M	2.83M	4.09M	4.13M	3.33M	4.37M	5.47M
Deferred Taxes	49K	-83K	177K	131K	0	0	130K	0	0	0
Other Non-Cash Items	-1.65M	-3.36M	3.97M	1.45M	-400K	922K	-6.2M	-72K	2.4M	1.61M
Working Capital Changes	24.58M	3.3M	-1.99M	1.81M	5.65M	-4.57M	6.84M	-8.43M	-15.16M	107.51M
Change in Receivables	25.67M	-248K	-401K	698K	2.5M	-532K	-99K	603K	-14.8M	13.55M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-141K	2.59M	-2.85M	0	0	0	0	0	0	0
Cash from Investing+	-244K	-899K	-1.84M	-32.04M	-66.89M	28.33M	-53.66M	23.76M	65.64M	-105.29M
Capital Expenditures	-244K	-899K	-1.8M	-1.86M	-1.89M	-1.71M	-2.63M	-1.24M	-801K	-576K
CapEx % of Revenue	0.01%	0.04%	0.09%	0.26%	0.02%	0.11%	-	0.31%	0.05%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-40K	-178K	0	30.04M	-51.03M	25M	66.45M	-104.71M
Cash from Financing+	27.78M	78.79M	271K	109.38M	49.62M	-803K	40.75M	-1.35M	43.25M	-1.12M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-1.78M	-4.11M	71K	-2.35M	-441K	143K	-6K	-776K	0	-548K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	43.84M	-6.54M	-23.9M	-45.94M	53.34M	-61.22M	-68.32M	-74.81M	-61.21M	65.27M
FCF Margin %	1.12%	-0.28%	-1.18%	-6.39%	0.48%	-3.97%	-	-19.01%	-4.14%	2.39%
FCF Growth %	3.47%	-1.15%	-2.65%	-0.92%	2.16%	-2.15%	-0.12%	-0.09%	0.18%	2.07%
FCF per Share	0.79	-0.13	-0.42	-0.74	0.75	-0.85	-0.91	-0.90	-0.72	0.65
FCF Conversion (FCF/Net Income)	2.17x	0.80x	0.84x	0.87x	1.22x	0.96x	0.90x	1.04x	1.11x	-1.29x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	42.89%	-6.65%	-20.38%	-34.61%	20.19%	-25.38%	-32.63%	-35.29%	-32.91%	-37.31%
Return on Invested Capital (ROIC)	190.27%	-	-	-511.32%	64.58%	-66.31%	-56.58%	-36.28%	-35.61%	-47.03%
Gross Margin	56.39%	-11.03%	-61.26%	-515.47%	54.34%	-285.5%	-	100%	-268.93%	-129.12%
Net Margin	51.85%	-30.57%	-130.39%	-708.24%	41.14%	-401.28%	-	-1798.04%	-366.41%	-186.44%
Debt / Equity	-	-	0.00x	0.00x	0.01x	0.01x	0.01x	0.02x	0.02x	0.05x
Interest Coverage	716.31x	-40.84x	-153.33x	-148.35x	23.12x	-332.93x	-135.99x	-199.57x	-304.68x	-393.82x
FCF Conversion	2.17x	0.80x	0.84x	0.87x	1.22x	0.96x	0.90x	1.04x	1.11x	-1.29x
Revenue Growth	29.14%	-40.61%	-12.75%	-64.48%	1435.39%	-86.03%	-100%	-	276.14%	84.51%

Frequently Asked Questions

Growth & Financials

AC Immune S.A. (ACIU) reported $4.4M in revenue for fiscal year 2024. This represents a 49% decrease from $8.6M in 2013.

AC Immune S.A. (ACIU) grew revenue by 84.5% over the past year. This is strong growth.

AC Immune S.A. (ACIU) reported a net loss of $71.9M for fiscal year 2024.

Dividend & Returns

AC Immune S.A. (ACIU) has a return on equity (ROE) of -37.3%. Negative ROE indicates the company is unprofitable.

AC Immune S.A. (ACIU) had negative free cash flow of $47.7M in fiscal year 2024, likely due to heavy capital investments.